ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial

Sentinel-Lymphknoten-Detektion beim Mammakarzinom mittels Fluoreszenztechnik – eine Alternative zum Technetiumverfahren?

Authors
E.-M. Grischke, C. Röhm, M. Hahn, G. Helms, S. Brucker, D. Wallwiener

Affiliation
Universitäts-Frauenklinik Tübingen, Tübingen

Abstract

Introduction: Detection of sentinel lymph nodes (SLN) is the standard procedure to evaluate axillary lymph node status in breast cancer. In addition to known and established procedures such as the blue dye method and scintigraphy, this study investigated the efficacy of a method based on use of the fluorescent dye indocyanine green (ICG).

Patients and Method: A total of 126 women with breast cancer histologically verified by punch biopsy were studied during surgical removal of SLN. In addition to SLN marking with technetium and scintigraphy, intra-individual comparison was done using indocyanine green (ICG) for marking instead of the standard blue dye.

Results: Scintigraphy had a detection rate of 96%; the detection rate with ICG was just under 89%. A body mass index (BMI) > 40 was found to be a limiting factor for the fluorescent method. Investigation into potential toxicities associated with the use of the fluorescent dye indocyanine green (ICG) for marking instead of the standard blue dye.

Conclusion: The ICG fluorescence technique for the detection of SLN was found to be a valid and feasible method in clinical practice when compared directly with the blue dye method and scintigraphy.

Zusammenfassung


Patientinnen und Methoden: Untersucht wurden dabei insges. 126 Patientinnen mit durch Stanzbiopsie histologisch gesichertem Mammakarzinom im Rahmen der operativen Entfernung des SLN. Neben einer standardmaßigen szintigrafischen Markierung des SLN mittels Technetium erfolgte im intraindividuellen Vergleich anstelle der üblichen Blaumarkierung die Markierung mittels Indocyaningrün (ICG).

Ergebnisse: Es konnte mit der Szintigraphie eine Detektionsrate von 96% erreicht werden, mittels ICG eine Rate von knapp 89%. Als limitierender Faktor für das Fluoreszenzverfahren erwies sich ein Body-Mass-Index > 40 (BMI > 40). Die Erfassung von möglicherweise auftretenden Toxizitäten bei Anwendung des Fluoreszenzfarbstoffs ICG ergab keinen Hinweis auf systemische oder auch lokale Nebenwirkungen. Im Kostenvergleich erweist sich die Fluoreszenztechnik als deutlich kostengünstiger als das szintigrafische Verfahren.

Schlussfolgerung: Die SLN-Detektion mittels Fluoreszenzverfahren durch Einsatz von ICG erweist sich im klinischen Einsatz und direktem Vergleich zur blauen Farbstoffmethode und dem szintigrafischen Verfahren als valides und praktikables Verfahren.
Introduction

The diagnosis and treatment of early-stage breast cancer has improved significantly in the last few decades through the use of better diagnostic methods (including mammogram screening) as well as a better understanding of tumor biology in terms of gene signatures and risk prediction models [1–4]. Reducing the extent of radical surgery in the axilla was another important step. Axillary lymph node status continues to be one of the most important prognostic factors [5–7]. This means that histopathological assessment of node status is still an integral part of the surgical treatment of invasive breast cancer. The introduction of sentinel lymph node biopsy (SLNB) was a first step on the way to reducing the extent of radical surgery and the secondary morbidity associated with axillary lymph node dissection such as pain, impaired sensitivity and lymph edema.

The SLNB method already existed and was primarily used to treat tumor entities such as malignant melanoma, prostate cancer, gastrointestinal tumors and bronchial carcinoma. Scintigraphy combined with the radionuclide technetium-99m was the first method generally used to mark SLN. Scintigraphy has a learning curve but detection rates with scintigraphy are now well over 90%, with a sensitivity of 91.2% and a false negative rate of 8.8% [9]. The literature reports detection rates between 86% (sensitivity 89%, false negative rate of 9.1%) and 96.2% (false negative rate 3.7%). Detection rates have improved as the technique has been optimized, intensifying the learning curve [10–13]. In the wake of the technetium method, a number of other methods including marking with blue dye were quickly developed and established in clinical practice. The combination of both methods has low false negative rates of just 5–10% and higher detection rates. In the literature there are reports of detection rates of 100% for scintigraphy and 92.9% for Patent blue dye marking [14]. As scintigraphy is associated with not inconsiderable costs, not least because of the requirement of a clinic or department of nuclear medicine, this has meant that certain centers, particularly in England, only perform marking with blue dye or assited limited axillary lymph node dissection after blue dye marking [15, 16]. The often limited availability of the radionuclide has also encouraged the trialing and use of other new detection methods. This has resulted in the development of a fluorescent method using the fluorescent dye indocyanine green (ICG) [17]. In addition to studies on its use in the treatment of breast cancer, there are a number of other reports on its use to treat malignant melanoma, or more generally in dermatosurgery, small cell lung cancer, and gastrointestinal tumors.

Studies have shown that ICG fluorescence imaging alone or in combination with the blue dye method or the radionuclide method is a safe and easy technique. Detection rates range from 100% for technetium, 92.9% for the blue dye method and 99.3% for ICG [14]. A direct comparison between the two dye methods found that ICG was more sensitive, with a reported sensitivity of 99%, compared to the blue dye method which had a sensitivity of 78% [18]. This study aimed to investigate the efficacy of the ICG fluorescence technique and compare it to the use of technetium in a prospective study which simultaneously aimed to record potential systemic or local toxicities. The decision was taken not to use any other dye, in this case, not to use the blue dye method, to avoid possible interactions between the two dye methods.

Material and Method

Study design

A total of 126 patients were investigated in a non-randomized single-center phase II trial. SLN detection was done using conventional technetium marking as well as fluorescence detection using intradermal injection of the ICG dye done in parallel for intra-individual comparison. The numbers of lymph nodes detected with the two methods were recorded and compared for individual patients as were the total number of SLNs detected using the two different methods. To assess how well ICG was tolerated, core data such as BMI and biosafety as well as potential reactions such as permanent skin marking were recorded.

Technetium marking and fluorescence imaging

Patients with breast cancer verified by punch biopsy who met the inclusion and exclusion criteria for SLNB were included in the study. Indications for SLNB were based on the relevant guideline currently valid in Germany [7]. Patients received 99mTc Nanocoll® and indocyanine green (ICG, obtained from Pulsion) for SLN detection. The commercially available Nanocoll® kit (human albumin 500 µ/vial; GE Healthcare) was used for technetium marking. Nanocoll® was reconstituted with sodium pertechnetate (99mTc) to prepare the technetium–99m albumin nanocolloid injection solution. The administered 99mTc Nanocoll solution was injected subcutaneously in the periaerolar region according to protocol. The analogue was administered in a dose of 39–102 MBq according to standard clinical practice. The preparation was administered on the afternoon of the day preceding surgery or on the day of surgery itself. If a two-day protocol was followed, the standard injected dose was 50–80 MBq TC; the standard dose administered to patients treated according to the one-day protocol was 20–40 MBq TC.

ICG Pulsion was prepared immediately prior to surgery. A vial containing 25 mg indocyanine green (trial medication) was prepared with 5 ml distilled water. Immediately preoperatively patients received an intradermal injection of 2 ml of the ICG solution (10 mg) administered in the periaerolar region to the breast quadrant in which the tumor resided. This was followed by a 10–15 minute massage until the start of fluorescence detection. A special charge-coupled camera with light-emitting diodes that generate light at a wavelength of 760 nm and which simultaneously registers the fluorescence signal was used. The CCD camera filters light with a wavelength of less than 820 nm. Fluorescence signals were continuously displayed in real-time as black and white images [19].

In the clinical trial, lymph drainage pathways were followed from the site of injection to the axilla (Fig. 1). Sentinel lymph nodes were assumed to be present when lymph drainage pathways ceased, indicating penetration of the fluorescent dye into deeper subcutaneous tissue layers. The skin was marked at these sites using conventional marking techniques. Fluorescence penetrates human tissue to a depth of 1.5–2 cm, meaning that with this approach fluorescence can be detected at a maximum of depth of 2 cm. A fluorescent lymph node was detected in most patients (Fig. 2). Conventional detection of SLN marked in advance with technetium was done immediately after fluorescence imaging. Radioactivity of the SLN or group of nodes detected by fluorescence was routinely checked. Counts per second (CPS) were determined at the gamma probe of the Neoprobe gamma detection system, with TC activity indicated by conversion of CPS to MBq.
The lymph node was then resected after renewed examination and recording of fluorescence (Fig. 3).

Subsequently, both methods were reviewed according to standard clinical practice in terms of additional detectable lymph nodes. If more signals or fluorescence were detected, additional lymph nodes were also resected.

Data collection and analysis
Histopathologic examination of individual marked and resected SLNs was done separately and results were recorded. The method used to detect the SLN was recorded. There were only a few cases where the two detection methods differed with respect to individual lymph node groups. In the overall assessment, detection using the two methods was recorded for each individual patient or axilla, not according to individual SLNs. To compare our results with those of the literature the total number of lymph nodes detected with the respective methods was also recorded.

Toxicity
As this was a phase II trial, patient tolerance of the fluorescent dye ICG obtained from Pulsion and all potential side effects were recorded. Organ toxicity and local toxicity after intradermal injection were assessed. ICG has been approved for intravenous administration. In this study ICG was administered by intradermal injection rather than by the standard intravenous route. Routine laboratory tests were performed after intradermal ICG administration together with local examination of the injection site. Particular attention was paid to any discoloration of the skin or tattooing, and all skin reactions including reddening or swelling were recorded.

Results
Patient characteristics and tumor stage
A total of 126 patients were recruited into the study. In 17 patients, the fluorescent dye was not administered according to study protocol. These patients were subsequently excluded from analysis. Another 4 patients with suspicion of tumor involvement of the axillary lymph nodes based on imaging and palpation had no indication for SLN biopsy. The data of 105 patients were ultimately included in the analysis. Five patients had bilateral cancer. The mean patient age was 57.5 years; 5 patients were older than 80 years (81, 82 and 3 × 84 years). The most common tumor stage in the overall patient population was pT2 in 43 cases, followed by tumor stage pT1c in 42 cases. Three patients had tumor stage pT1a, and 21 patients had tumor stage pT1b. A total of 17 patients had either extensive pTis or pTmic. G 1 grade was present in 23% of patients, G 2 in 45% and G 3 in 32%.

The mean BMI was 26 ± 5.32. Three patients had a BMI > 40.

Detection of lymph nodes
Intra-individual comparison of lymph node detection using technetium and ICG
Of 105 patients whose data were available for analysis, SLN detection using technetium was achieved in 104 cases, which corre-
sponds to a detection rate of 98%. When ICG was used, SLN detection was achieved in 93 patients, which corresponds to a detection rate of 89%. SLN detection with ICG and technetium was achieved in 91 of 105 patients. SLN were identified using ICG but not technetium in 2 of 105 patients; SLN were identified using technetium but not ICG in 12 of 100 patients (Table 1). Using both methods, a total of 162 SLN were identified and resected. A total of 157 SLN were detected using technetium (96%), while 138 SLN (85%) were identified using ICG. Overall, 96% of SLN were identified using technetium (BMI 40.4 and 40.9, respectively). The time from injection to the start of SLN detection was at least 10 minutes; the maximum time from injection to detection was 25 minutes in accordance with the study protocol and the approach used for breast surgery. The time from the start of detection to SLN excision was 8–10 minutes.

**SLN detection using both methods irrespective of tumor involvement**

In 91 patients SLN were detected using both ICG and technetium, with SLN subsequently resected and investigated for tumor involvement. In the group of patients in whom SLN were detected using technetium but not identified with ICG, 2 patients were found to have tumor involvement. In the group in whom SLN were detected with both technetium and ICG, histological investigation identified tumor involvement of the SLN in 25 patients (Table 2). In the group of patients in whom SLN could not be identified with either of the methods, the histological results were reviewed. No correlation was found between non-detection of lymph nodes and histopathological evidence of lymph node involvement.

**Influence of other variables on fluorescence detection importance of body mass index (BMI)**

The detection rate with ICG in patients with a BMI of less than 40 (<40 BMI) was 89%. There was no difference in detection rate when a cut-off of BMI < 30 or 35 was used. Detection with ICG was only difficult in patients with BMI > 40. No SLN was detected using the fluorescence method in 2 of 3 patients with a BMI > 40. This could be explained by the fact that the fluorescence method is only considered adequate at a maximum penetration depth of 2 cm.

**Pharmaceutical drug safety**

**Systemic and local toxicity**

To investigate the pharmacological safety of the fluorescent dye used, all side effects occurring subsequent to the administration of ICG were recorded. Side effects were limited and of only mild to moderate severity (grade I and II) and were not related to the intradermal injection of ICG (Table 4). There were no therapeutic consequences. No local skin changes such as allergic reactions or permanent skin tattoos occurred. The safety profile of ICG administered by intradermal injection did not differ from that of ICG administered intravenously.

**Discussion**

SLNB is an accepted and validated standard procedure for axillary staging; it is performed during primary surgery in women with breast cancer whose SLN status is clinically and morphologically unremarkable. The most commonly used procedure for SLNB with a low false negative rate of just 9.8% consists of combining blue dye and the radionuclide technetium 99 m for SLN detection [8].

A number of large studies with a median follow-up time of 97 months have shown that there is no difference between the SNB

---

**Table 1** SLN detection with TC and fluorescence technique in 105 patients.

<table>
<thead>
<tr>
<th>Detection</th>
<th>N</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Detected with TC</td>
<td>n = 103 (98%)</td>
<td></td>
</tr>
<tr>
<td>Detected with ICG</td>
<td>n = 93 (89%)</td>
<td></td>
</tr>
<tr>
<td>SN identified using ICG and TC in</td>
<td>n = 91/105</td>
<td></td>
</tr>
<tr>
<td>SN identified with ICG but not TC in</td>
<td>n = 2/105</td>
<td></td>
</tr>
<tr>
<td>SN identified with TC but not ICG in</td>
<td>n = 12/105</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2** Overall numbers of SLN detected using the two methods.

<table>
<thead>
<tr>
<th>Detection</th>
<th>N</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of identified SLN</td>
<td>162</td>
<td></td>
</tr>
<tr>
<td>Number of SLN detected with TC</td>
<td>n = 157 (96%)</td>
<td></td>
</tr>
<tr>
<td>Number of SLN detected with ICG</td>
<td>n = 138 (85%)</td>
<td></td>
</tr>
<tr>
<td>Number of SLN detected with TC and ICG</td>
<td>n = 133 (82%)</td>
<td></td>
</tr>
<tr>
<td>Sensitivity (0.96 CI)</td>
<td>0.92–0.99</td>
<td></td>
</tr>
<tr>
<td>Positive predictive value (0.85 CI)</td>
<td>0.78–0.9</td>
<td></td>
</tr>
<tr>
<td>Specificity (0.82 CI)</td>
<td>0.75–0.88</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3** Number of positive N+ lymph nodes (tumor involvement) according to the method used to identify SLN.

<table>
<thead>
<tr>
<th>Detection</th>
<th>N</th>
<th>Tumor Involvement</th>
</tr>
</thead>
<tbody>
<tr>
<td>SNL detected with ICG and TC</td>
<td>n = 91</td>
<td>N+ in n = 25</td>
</tr>
<tr>
<td>SNL detected with ICG but not TC</td>
<td>n = 2</td>
<td>N+ in n = 0</td>
</tr>
<tr>
<td>SNL detected with TC but not ICG</td>
<td>n = 12</td>
<td>N+ in n = 2</td>
</tr>
</tbody>
</table>

**Table 4** Events which occurred during assessment of toxicity.

<table>
<thead>
<tr>
<th>Screening No.</th>
<th>Event</th>
<th>Ongoing</th>
<th>Severe</th>
<th>Intensity</th>
<th>Relationship</th>
<th>Actions</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>063</td>
<td>tachycardia grade 2</td>
<td>0</td>
<td>no</td>
<td>mild</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>063</td>
<td>vomiting grade 1</td>
<td>0</td>
<td>no</td>
<td>mild</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>063</td>
<td>nausea grade 1</td>
<td>0</td>
<td>no</td>
<td>mild</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>083</td>
<td>pain during Redon suction drainage</td>
<td>0</td>
<td>no</td>
<td>moderate</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>111</td>
<td>nausea</td>
<td>0</td>
<td>no</td>
<td>moderate</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>111</td>
<td>vomiting</td>
<td>0</td>
<td>no</td>
<td>mild</td>
<td>not related</td>
<td>none</td>
<td>recovered/resolved</td>
</tr>
<tr>
<td>126</td>
<td>high leukocyte count (grade 2)</td>
<td>1</td>
<td>no</td>
<td>moderate</td>
<td>not related</td>
<td>none</td>
<td>no recovery/not resolved</td>
</tr>
</tbody>
</table>
and effective, particularly compared to a 5 mg dose [23]. These doses, with a dose of 10 mg ICG having been found to be safe administered ICG. The amount of ICG administered to patients in our patient cohort of 105 patients. A review of the literature showed rates reported for technetium (98%) and for ICG (89%) in a large of our study presented here correlate well with the detection SLN detection rate and that the false negative rate was comparably with that of the technetium method [19, 21, 26–29]. The data of our study presented here correlate well with the detection rates reported for technetium (98%) and for ICG (89%) in a large patient cohort of 105 patients. A review of the literature showed not insignificant methodological differences between studies in terms of the injection technique used and the amount of administered ICG. The amount of ICG administered to patients in our study was based on previous investigations into appropriate doses, with a dose of 10 mg ICG having been found to be safe and effective, particularly compared to a 5 mg dose [23]. These ICG doses have also been confirmed in other studies [19, 30–32]. Although there are a number of other studies, the only comparable study in terms of design and sufficient number of patients is the prospective study by Wishart et al., who investigated 100 patients [33]. With regard to the numbers of detected and resected lymph nodes, in their study the ICG detection rate was 100%, while detection rate with ICG and technetium was only 77.3%. In absolute numbers that means that 156 lymph nodes out of a total of 201 were detected using the radionuclide method, while all resected lymph nodes were identified using ICG fluorescence. Our figures showed that 136 out of a total of 154 lymph nodes were detected with ICG, while the number of lymph nodes detected with technetium was 147 out of 154 resected lymph nodes. The data of the two studies are clearly comparable. Some studies investigated detection rates using both technetium and the blue dye method [33]. In addition to the above mentioned study by Wishart et al., one study also investigated larger numbers of patients (n = 411 patients) but they only compared ICG with the blue dye method [18]. Another larger study with 142 patients which compared ICG only with the blue dye method was a retrospective study [29].

Our study was expressly designed to compare ICG with the technetium, the current gold standard, and chose not to do an additional comparison with the blue dye method. The reason was that this study aimed to investigate prospectively whether it would be possible to forego technetium marking and use ICG for detection instead. Another consideration was that in the literature the detection rates for the blue dye method are lower compared to those for technetium. As our study also aimed to investigate the toxicity occurring after intradermal injection of ICG, our study deliberately avoided marking using the blue dye method. Studies which investigated larger numbers of patients and compared either technetium or the blue dye method with fluorescence marking have reported that the detection rates for ICG are only minimally lower compared to technetium marking. Comparative studies have demonstrated detection rates of 86 and 90%, respectively [10].

Based on the results of these studies, the detection rate for ICG of 89% in individual patients compared to technetium found in our study confirms that ICG is an effective and valid method. Comparisons between studies are complicated by the use of different methods, concentrations and analyses [34]. The correlation between lymph node detection and BMI, which has only been shown in this study, showed for the first time that the efficacy of the method is significantly correlated with BMI. The cut-off was determined as a BMI > 40. The explanation for this correlation is that imaging of lymph drainage channels using fluorescence is only possible to a maximum depth of 1.5–2 cm. Out of the total of 12 sentinel lymph nodes not detectable by ICG, 2 cases had a BMI > 40. In the overall patient population only 3 of 105 patients had a BMI > 40. There were no side effects associated with intradermal ICG administration, meaning that in terms of systemic side effects there was no difference between intradermal injection and intravenous administration. As with every approach used for SLNB, the practical application has a learning curve.

The average costs of the technetium method are between €300–350, while costs for the ICG fluorescence method are around €100. When, as is currently the case in most centers, technetium is combined with the blue dye method, the costs rise to €450–500. In addition to other quality criteria which need to be considered when planning breast cancer treatment, a cost-benefit analysis is also an important quality criterion [35].

**Conclusion**

SLN detection using the ICG fluorescence method has been shown to be a valid and effective method in clinical practice and in direct comparison with the technetium method. With a detection rate of 89% the rate for the ICG method was only slightly lower than the rate of 98% achieved with the standard technetium method.

This study is the first study to have demonstrated a correlation between SLN detection using fluorescence and patient BMI. In patients with a BMI > 40 the method has only limited efficacy as lymph drainage channels cannot be adequately visualized. Our study found no systemic or local toxicity after intradermal injection. In terms of costs, fluorescence imaging does not require the administration of a radionuclide which is required with technetium imaging; this means that the technical complexity and the costs are lower with the ICG approach.
The use of potential new technologies, particularly cameras with a higher resolution, is likely to lead to a higher acceptance of the method among users and even higher detection rates.

Conflict of Interest

None.

References